1. Home
  2. MODD vs INAB Comparison

MODD vs INAB Comparison

Compare MODD & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Modular Medical Inc.

MODD

Modular Medical Inc.

HOLD

Current Price

$1.65

Market Cap

11.2M

Sector

Health Care

ML Signal

HOLD

Logo IN8bio Inc.

INAB

IN8bio Inc.

HOLD

Current Price

$0.97

Market Cap

11.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MODD
INAB
Founded
1998
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.2M
11.8M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
MODD
INAB
Price
$1.65
$0.97
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $7.00
AVG Volume (30 Days)
★ 144.6K
36.7K
Earning Date
11-13-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.12
$0.88
52 Week High
$6.16
$2.73

Technical Indicators

Market Signals
Indicator
MODD
INAB
Relative Strength Index (RSI) 34.25 35.57
Support Level $0.28 $0.92
Resistance Level $2.49 $1.22
Average True Range (ATR) 0.34 0.09
MACD -0.05 -0.04
Stochastic Oscillator 2.76 20.33

Price Performance

Historical Comparison
MODD
INAB

About MODD Modular Medical Inc.

Modular Medical Inc is a development stage medical device company which focuses on the design, development, marketing and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

Share on Social Networks: